(NARI) – Press Releases
-
Inari Medical to Announce First Quarter 2024 Financial Results
-
Lowey Dannenberg, P.C. is Investigating Inari Medical Inc. (“Inari” or the “Company”) (NASDAQ:NARI) for Potential Violations of the Federal Securities Laws and Encourages Investors with more t
-
Inari Medical Announces the Release of 2023 Ethos and Sustainability Report
-
Lowey Dannenberg, P.C. is Investigating Inari Medical Inc. (“Inari” or the “Company”) (NASDAQ:NARI) for Potential Violations of the Federal Securities Laws and Encourages Investors with more t
-
Inari Medical Strengthens Senior Leadership Team with Addition of Two Executives
-
AppFolio Set to Join S&P MidCap 400; Inari Medical to Join S&P SmallCap 600
-
Bragar Eagel & Squire, P.C. Is Investigating SSR, Inari Medical, and Entravision and Encourages Investors to Contact the Firm
-
Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT Registry
-
Bragar Eagel & Squire, P.C. Is Investigating Thoughtworks, Chemours, Methanex, and Inari Medical and Encourages Investors to Contact the Firm
-
INARI MEDICAL ALERT: Bragar Eagel & Squire, P.C. is Investigating Inari Medical, Inc. on Behalf of Inari Medical Stockholders and Encourages Investors to Contact the Firm
-
Inari Medical Reports Fourth Quarter 2023 Financial Results
-
Inari Medical to Announce Fourth Quarter and Full Year 2023 Financial Results
-
Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance
-
OKAMI MEDICAL APPOINTS RHONDA ROBB AS PRESIDENT AND CHIEF EXECUTIVE OFFICER
-
Inari Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Inari Medical Announces First Patient Enrollment in PEERLESS II Randomized Controlled Trial (RCT)
-
Inari Medical Closes Acquisition of LimFlow
-
Inari Medical to Present at Upcoming Investor Conferences
-
LimFlow Announces Agreement to Be Acquired by Inari Medical
-
Inari Medical Reports Third Quarter 2023 Financial Results
-
Inari Medical Expands Its Patient-Focused Mission with Agreement to Acquire LimFlow
-
Inari Medical to Announce Third Quarter 2023 Financial Results
-
Inari Medical to Present at Upcoming Investor Conferences
-
Inari Medical Reports Second Quarter 2023 Financial Results
-
Inari Medical to Present at the 43rd Annual Canaccord Growth Conference
-
Inari Medical to Announce Second Quarter 2023 Financial Results
-
Inari Medical Announces Commercial Launch of RevCore™ and Triever16 Curve™, Two New Purpose-Built Products for Addressing Venous Stent Thrombosis and Venous Thromboembolism
-
Inari Medical Announces the Release of 2022 Ethos and Sustainability Report
-
Inari Medical Announces PEERLESS II, a Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever® System vs. Anticoagulation in Pulmonary Embolism Patients
-
Inari Medical Reports First Quarter 2023 Financial Results
-
Inari Medical to Present at the Bank of America 2023 Healthcare Conference
-
Inari Medical to Announce First Quarter 2023 Financial Results
-
FLAME Study Demonstrates 90% Survival Improvement in High-Risk Pulmonary Embolism with Inari Medical FlowTriever System
-
Inari Medical Reports Fourth Quarter and Full Year 2022 Financial Results
-
Inari Medical to Announce Fourth Quarter and Full Year 2022 Financial Results
-
Inari Medical to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
-
Inari Medical Announces First Patient Enrolled in the DEFIANCE Trial, Randomized Controlled Trial Evaluating Clinical Outcomes of the ClotTriever® System in Deep Vein Thrombosis
-
Inari Medical Announces Preliminary 2022 Revenue and 2023 Guidance
-
Inari Medical to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Inari Medical to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
-
Inari Medical Reports Third Quarter 2022 Financial Results
-
Inari Medical Announces In-hospital and 30-day Outcomes from the Fully Enrolled CLOUT Registry and Results from Propensity-Score Matched Comparison of CLOUT vs. ATTRACT
-
Inari Medical to Announce Third Quarter 2022 Financial Results
-
Inari Medical Announces Results from the Fully Enrolled 800-patient US Cohort of the FlowTriever FLASH Registry
-
Inari Medical to Host First Analyst & Investor Day
-
Inari Medical Announces Three New Data Sets to be Presented During Late-Breaking Clinical Trial Sessions at the 2022 TCT and VEINS Conferences
-
Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes of the ClotTriever® System in Deep Vein Thrombosis
-
Inari Medical to Present at Upcoming Investor Conferences
-
Inari Medical Announces Leadership Succession Plan
-
Inari Medical Reports Second Quarter 2022 Financial Results
Back to NARI Stock Lookup
